Start Date
June 14, 2022
Primary Completion Date
August 31, 2024
Study Completion Date
August 31, 2025
Pemigatinib 4.5 MG
"Pemigatinib 4.5 mg tablets taken 3 times per day \[daily dose of 13.5 mg (3 tablets)\] for 14 consecutive days followed by 7 days off medication in 21-day cycles~Doses will be self-administered at home. Participants will be instructed to take study medication at the same time each day, with or without food."
HonorHealth Research Institute, Scottsdale
Lead Sponsor
Collaborators (1)
Incyte Corporation
INDUSTRY
HonorHealth Research Institute
OTHER